(MET) MetLife - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US59156R1086

MET: Insurance, Annuities, Employee Benefits, Asset Management

MetLife, Inc. (NYSE: MET) is one of the largest financial services companies globally, specializing in insurance, annuities, employee benefits, and asset management. Incorporated in 1999 and headquartered in New York, the company operates across six distinct segments: Retirement and Income Solutions, Group Benefits, Asia, Latin America, Europe, the Middle East and Africa (EMEA), and MetLife Holdings. This diversified structure allows MetLife to cater to a wide range of customers, from individuals to large corporations, across various geographic regions.

MetLife’s product portfolio is extensive, covering life, dental, disability, and accident insurance, as well as annuities and pension risk transfer solutions. The company also offers administrative services for employers, prepaid legal plans, and a variety of investment products tailored for institutional clients. Its services extend to structured settlements, longevity reinsurance, and credit insurance, making it a comprehensive provider in the life and health insurance space. Additionally, MetLife provides funding agreements and synthetic guaranteed interest contracts, which are critical for organizations looking to manage their financial obligations effectively.

From a financial standpoint, MetLife is a substantial player in the industry, with a market capitalization of approximately $56.7 billion. The company’s price-to-earnings (P/E) ratio stands at 13.43, with a forward P/E of 8.46, indicating expectations of future earnings growth. Its price-to-book (P/B) ratio of 2.07 reflects the market’s valuation of its assets and liabilities. The price-to-sales (P/S) ratio of 0.80 suggests that the company is reasonably valued relative to its revenue generation. These metrics are important for investors and fund managers assessing MetLife’s position in the life and health insurance sector.

MetLife’s global presence, diverse product offerings, and significant scale make it a key player in the insurance and financial services industry. Its ability to navigate different markets and provide tailored solutions positions it as a stable investment opportunity, particularly for those seeking exposure to the life and health insurance sector. For more information, visit their website at https://www.metlife.com.

Additional Sources for MET Stock

MET Stock Overview

Market Cap in USD 56,749m
Sector Financial Services
Industry Insurance - Life
GiC Sub-Industry Life & Health Insurance
IPO / Inception 2000-04-05

MET Stock Ratings

Growth 5y 71.8%
Fundamental 23.3%
Dividend 44.3%
Rel. Strength Industry -6.94
Analysts 4.2/5
Fair Price Momentum 80.85 USD
Fair Price DCF 237.90 USD

MET Dividends

Dividend Yield 12m 2.78%
Yield on Cost 5y 5.24%
Annual Growth 5y 3.44%
Payout Consistency 34.6%

MET Growth Ratios

Growth Correlation 3m 1.1%
Growth Correlation 12m 85.3%
Growth Correlation 5y 86.1%
CAGR 5y 14.22%
CAGR/Max DD 5y 0.27
Sharpe Ratio 12m 0.81
Alpha 3.93
Beta 0.84
Volatility 20.03%
Current Volume 3282.8k
Average Volume 20d 3668.3k
What is the price of MET stocks?
As of February 23, 2025, the stock is trading at USD 81.01 with a total of 3,282,809 shares traded.
Over the past week, the price has changed by -0.84%, over one month by -6.15%, over three months by -4.29% and over the past year by +21.02%.
Is MetLife a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, MetLife is currently (February 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 23.31 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MET as of February 2025 is 80.85. This means that MET is currently overvalued and has a potential downside of -0.2%.
Is MET a buy, sell or hold?
MetLife has received a consensus analysts rating of 4.20. Therefor, it is recommend to buy MET.
  • Strong Buy: 7
  • Buy: 5
  • Hold: 2
  • Sell: 1
  • Strong Sell: 0
What are the forecast for MET stock price target?
According to ValueRays Forecast Model, MET MetLife will be worth about 93.8 in February 2026. The stock is currently trading at 81.01. This means that the stock has a potential upside of +15.83%.
Issuer Forecast Upside
Wallstreet Target Price 94.7 16.9%
Analysts Target Price 94.4 16.5%
ValueRay Target Price 93.8 15.8%